Pulmonary Fibrosis

Pulmonary fibrosis can occur without a clear inciting agent, but it is more commonly associated with severe lung injury. Reported associated causes or settings include respiratory infections, chronic granulomatous diseases, medications, connective tissue disorders, and infection-related lung injury such as SARS, MERS, and SARS-CoV-2.

The disease is characterized by progressive fibrotic remodeling of the lung, with replacement of normal alveolar tissue by fibroblasts and collagen. The resulting architectural distortion causes irreversible lung dysfunction and impaired oxygen transfer into the bloodstream. Genetic factors also contribute to disease biology, including rare variants and common single-nucleotide polymorphisms.

Risk is increased by severe lung injury and by conditions associated with pulmonary fibrosis, including respiratory infections, chronic granulomatous diseases, medications, and connective tissue disorders. Genetic susceptibility is also a risk factor, including common SNPs such as the MUC5B promoter variant and other heritable contributors.

The supplied grounding supports management at the level of broad therapeutic strategies rather than specific regimens. These include diagnosis- and phenotype-guided management of fibrotic interstitial lung disease, with attention to therapeutic strategies for associated conditions such as rheumatoid arthritis-associated ILD and risk-reduction approaches in post-infectious fibrosis. The literature also emphasizes using genetic information to inform prognosis and treatment response.